Advertisement
DHR vs IQV
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. IQVIA Holdings Inc. (IQV) Stock Comparison
Key Takeaways
- DHR recently reported Q1 earnings with an EPS beat but slight revenue miss, contributing to a pullback in recent market activity.
- IQV awaits its Q1 earnings release, amid ongoing AI-related developments and sector pressures.
- DHR trades at a higher trailing P/E ratio (price-to-earnings, 33.88) compared to IQV's 20.12, reflecting premium valuation for its diversified life sciences portfolio.
- Both stocks have faced downward pressure in recent weeks, with DHR showing sharper 1-month declines amid acquisition-related debt.
- Tickeron's analysis positions DHR as a stronger long-term buy relative to IQV.
- Market sentiment reflects caution in healthcare stocks, but growth in biotech and data analytics remains a key driver for both.
Introduction
DHR and IQV operate in the overlapping life sciences and healthcare sectors, making them compelling for comparison among investors seeking exposure to diagnostics, biotechnology, and clinical research. Danaher focuses on instruments and consumables, while IQVIA emphasizes data analytics and contract research. Traders monitoring relative performance may find value in their contrasting valuations, momentum shifts, and sector catalysts. This stock comparison highlights recent price behavior, business drivers, and market positioning to aid informed decision-making in the current environment, where healthcare innovation meets macroeconomic pressures.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global leader in life sciences, diagnostics, and biotechnology, providing instruments, consumables, and services across its Biotechnology, Life Sciences, and Diagnostics segments. With a market cap of approximately $124 billion, the company supports therapeutics development, lab automation, and clinical diagnostics.
In recent market activity, DHR shares have declined, trading around $175 with a trailing P/E of 33.88 and forward P/E of 20.66. Q1 2026 earnings showed EPS of $2.06, beating estimates, though revenue slightly missed, alongside a $908 million charge impacting results. A euro debt raise for the Masimo acquisition (mergers and acquisitions, M&A) has influenced sentiment, contributing to 1-month and 3-month drops of about 9% and 22%, respectively. Broader YTD performance reflects volatility in healthcare demand, with analysts maintaining overweight ratings but adjusting targets downward.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) delivers clinical research, analytics, and healthcare intelligence through its Technology & Analytics, R&D Solutions, and Contract Sales segments, serving pharma and biotech firms. Its $26 billion market cap underscores a focus on real-world data and trial management.
Shares recently hovered near $158, with a trailing P/E of 20.12 and attractive forward P/E of 12.36. Recent weeks have seen modest declines amid AI-related concerns in contract research, despite a launch of IQVIA.ai with NVIDIA. Q4 2025 results topped estimates, but weak 2026 guidance pressured the stock earlier. Upcoming Q1 earnings on May 5 add anticipation, with YTD returns outperforming in some metrics amid sector rotation. Sentiment balances growth in data services against high debt levels (debt-to-equity 246%).
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies. These bots employ AI/ML for real-time signals, featuring styles like trend following, swing trading, and volatility plays on sectors such as semiconductors, industrials, and small caps. Standout stats include annualized returns from 24% to 163%, win rates of 51% to 88%, and profit factors up to 11.7, with drawdowns managed via take-profit/stop-loss (e.g., 3%/2%). Multi-agent bots on high-growth themes like AI infrastructure have delivered 97% returns, beating benchmarks. Only the most suitable for current conditions earn a spot, offering varied timeframes from minutes to days. Explore these tools to enhance your trading edge.
Head-to-Head Comparison
DHR boasts a broader business model with diversified revenue from instruments and biotech consumables, contrasting IQV's specialization in data-driven R&D and analytics. Growth drivers differ: Danaher leverages M&A like Masimo for expansion, while IQVIA benefits from AI integrations and clinical trial demand. Recent momentum favors neither decisively, with both facing healthcare sector headwinds—DHR down sharply post-earnings, IQV pressured by CRO (contract research organization) selloffs.
Risk factors include DHR's higher leverage from deals and IQV's elevated debt/equity. Sector exposure overlaps in life sciences but DHR offers diagnostics stability versus IQVIA's analytics growth. Valuation trade-off: IQV's lower forward P/E signals value, while DHR commands a premium for scale. Market sentiment tilts toward caution, with analysts favoring DHR long-term but noting IQV's relative affordability.
Tickeron AI Verdict
Tickeron's AI models currently favor DHR over IQV for long-term positioning, citing superior trend consistency, diversified catalysts, and relative stability in life sciences tools. While IQV offers valuation appeal and AI upside potential, DHR's scale and post-earnings resilience suggest higher probability of outperformance amid market recovery. Observable factors like analyst targets (DHR ~$250) and sector momentum support this edge, though short-term volatility persists for both.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a StrongBuy and IQV is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileIQV’s FA Score has 0 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- IQV’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 5 TA indicator(s) are bullish while IQV’s TA Score has 6 bullish TA indicator(s).
- DHR’s TA Score: 5 bullish, 4 bearish.
- IQV’s TA Score: 6 bullish, 3 bearish.
Price Growth
DHR (@Medical Specialties) experienced а +0.89% price change this week, while IQV (@Medical Specialties) price change was +0.68% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.28%. For the same industry, the average monthly price growth was +13.41%, and the average quarterly price growth was -7.34%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
IQV is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Medical Specialties (-3.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | IQV | DHR / IQV | |
| Capitalization | 132B | 31.2B | 423% |
| EBITDA | 7.08B | 3.52B | 201% |
| Gain YTD | -19.320 | -18.615 | 104% |
| P/E Ratio | 35.72 | 22.79 | 157% |
| Revenue | 24.8B | 16.6B | 149% |
| Total Cash | 5.7B | 2.1B | 271% |
| Total Debt | 18.5B | 16.1B | 115% |
DHR | IQV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 81 | 43 | |
PRICE GROWTH RATING 1..100 | 57 | 50 | |
P/E GROWTH RATING 1..100 | 55 | 39 | |
SEASONALITY SCORE 1..100 | 21 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is somewhat better than the same rating for IQV (61) in the Servicestothe Health Industry industry. This means that DHR’s stock grew somewhat faster than IQV’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that DHR’s stock grew similarly to IQV’s over the last 12 months.
IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for DHR (81) in the Medical Specialties industry. This means that IQV’s stock grew somewhat faster than DHR’s over the last 12 months.
IQV's Price Growth Rating (50) in the Servicestothe Health Industry industry is in the same range as DHR (57) in the Medical Specialties industry. This means that IQV’s stock grew similarly to DHR’s over the last 12 months.
IQV's P/E Growth Rating (39) in the Servicestothe Health Industry industry is in the same range as DHR (55) in the Medical Specialties industry. This means that IQV’s stock grew similarly to DHR’s over the last 12 months.
| DHR | IQV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | N/A |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 66% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 62% |
| Advances ODDS (%) | 3 days ago 54% | 3 days ago 58% |
| Declines ODDS (%) | 5 days ago 61% | 12 days ago 65% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 59% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 53% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -1.25% | ||
| TMO - DHR | 77% Closely correlated | -1.91% | ||
| A - DHR | 73% Closely correlated | -2.12% | ||
| RGEN - DHR | 68% Closely correlated | -3.35% | ||
| RVTY - DHR | 65% Loosely correlated | -3.94% | ||
| BIO - DHR | 64% Loosely correlated | -4.28% | ||
More | ||||